A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Completed · Phase 3 · Has a placebo group

Conditions studied: Lambert Eaton Myasthenic Syndrome

In brief

A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

Key facts

Study ID

NCT01377922

Run by

Catalyst Pharmaceuticals, Inc.

People needed

38

Starts

2011-06-01

Expected to finish

2016-07-01

Last updated by the study team

2018-01-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Scottsdale, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — Palo Alto, California, United States
• Study site — Kansas City, Kansas, United States
• Study site — New York, New York, United States
• Study site — Lyon, France
• Study site — Munich, Bavaria, Germany
• Study site — Berlin, Germany
• Study site — Pécs, Hungary
• Study site — Warsaw, Poland
• Study site — Moscow, Russia
• Study site — Belgrade, Serbia
• Study site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.